Supreme Court exposes GlaxoSmithKline to Humana's Avandia-spending claims

The U.S. Supreme Court declined to consider an appeal from GlaxoSmithKline ($GSK) in a fight over Humana's spending on the company's disgraced diabetes drug Avandia. The ruling not only opens GSK to the Humana suit, which applies to its Medicare Advantage plans, but also to potential lawsuits from other insurers. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.